Mirum Stock Jumps 12% on Positive Volixibat Trial Data

Key Trial Success

Mirum Pharmaceuticals (NASDAQ:MIRM) shares surged 12% after announcing positive results from its VISTAS Phase 2b study for the drug volixibat. The trial focused on patients with primary sclerosing cholangitis (PSC), a chronic liver disease with no currently approved treatments.

The study successfully met its primary endpoint, demonstrating a statistically significant improvement for patients treated with the drug.

Clinical Study Overview

The trial data showed a 1.64 point placebo-adjusted reduction in pruritus, or severe itching, as measured by the Adult ItchRO scale. This result was statistically significant with a p-value of 0.0019.

Furthermore, 55.6% of patients receiving volixibat achieved at least a 2-point reduction in the itch score, compared to only 26.3% of those on placebo. The treatment also significantly reduced serum bile acids.

Market Impact and Analyst View

The positive clinical data triggered a strong market response and reinforced analyst confidence in the company's pipeline. Baird reiterated its Outperform rating on MIRM stock with a price target of $112.00, citing increased confidence in Mirum's specialized positioning in hepatology.

Following these results, Mirum plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of 2026.

Summary and Future Outlook

Mirum is scheduled to present the full study findings at a major liver congress on May 30. The company is also advancing volixibat in another trial for primary biliary cholangitis, with topline data expected in the first quarter of 2027, marking a key future catalyst to monitor.

FAQ

Q: Why did Mirum Pharmaceuticals' stock increase?
A: The stock rose 12% because its drug, volixibat, showed positive and statistically significant results in a Phase 2b clinical trial for treating primary sclerosing cholangitis (PSC).

Q: What is the next regulatory step for volixibat?
A: Mirum plans to meet with the U.S. FDA in the summer of 2026 and intends to submit a New Drug Application for volixibat in the second half of 2026.

Source: Investing.com